middle.news
ImpediMed’s SOZO Platform Gains FDA Clearance for Sarcopenia Risk Assessment
9:50am on Wednesday 19th of August, 2026 AEST
•
Healthcare
Read Story
ImpediMed’s SOZO Platform Gains FDA Clearance for Sarcopenia Risk Assessment
9:50am on Wednesday 19th of August, 2026 AEST
Key Points
SOZO receives FDA clearance for sarcopenia risk assessment
Only FDA-cleared bioimpedance spectroscopy device for this use
Sarcopenia affects one-third of breast cancer patients during chemotherapy
Non-invasive, repeatable muscle mass monitoring integrated into existing SOZO scans
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Impedimed (ASX:IPD)
OPEN ARTICLE